Hainan Honz Pharma's Main Product Faces Partial SFDA Ban  
5/24/2011 12:58:26 PM

May 24, 2011 -- Hainan Honz Pharmaceutical announced its net income for the first half of 2011 will fall around 50%. The company has watched its stock price drop precipitously after its major product, Ruizhiqing, has been blamed for as many as seven deaths. Recently, the SFDA prohibited the use of the drug in children under 12. The drug is thought to cause liver damage and has been banned in many of the countries in which it was approved. More details....

Stock Symbol: (SHE: 300086)